Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Yahoo! Finance]
Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses